Heidelberg Pharma Research GmbH
Torsten Hechler has a significant work experience in the field of pharmaceutical research and cancer research. Torsten started their career as a Postdoc at the Technische Universität Darmstadt in 2007 and then moved to the German Cancer Research Center (dkfz) in 2008, where they worked as a Postdoc until 2011. Torsten then joined Heidelberg Pharma GmbH in 2011 as a Gruppenleiter, and after four years, they moved to Heidelberg Pharma Research GmbH in 2015, where they held various roles including Abteilungsleiter, Vice President, and currently holds the position of Senior Vice President. Torsten'sexpertise spans across different aspects of the pharmaceutical industry, making him a valuable asset in their field.
Torsten Hechler obtained their Dr. rer. nat. degree in Biology from Technische Universität Darmstadt between 2003 and 2007.
This person is not in any teams
This person is not in any offices
Heidelberg Pharma Research GmbH
Heidelberg Pharma AG based in Ladenburg, Germany, is a biopharmaceutical company listed on the Frankfurt Stock Exchange in the Regulated Market / Prime Standard. Heidelberg Pharma is focused on oncology and is the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary platform is being applied to develop the Company’s own therapeutic ATACs and third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA-ATAC for multiple myeloma. Former clinical assets MESUPRON® and REDECTANE® have been partnered. Our mission is to research and develop therapies for cancer patients enabling them to receive a targeted and tailor-made course of treatment that is both highly effective and as well-tolerated as possible.